Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in miceMolecular Psychiatry · 2026-07-07The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026-05-01Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronseLife · 2026-03-27Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsResearch Square · 2026-01-07Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativitybioRxiv · 2025-11-07Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigmUniversität Zürich, ZORA · 2025-11-05[Acceptance of psilocybin-assisted therapy in German-speaking countries].Der Nervenarzt · 2025-11-01Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.Psychopharmacology · 2025-08-01Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances.Swiss medical weekly · 2025-07-01Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.Neuropharmacology · 2025-05-01Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländernedoc Publication server (Humboldt University of Berlin) · 2025-02-12Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.Frontiers in psychiatry · 2025-01-01Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.Neuroscience applied · 2025-01-01The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelicsPsyArXiv · 2024-10-22Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch NegativityResearch Square · 2024-09-26Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.The Cochrane database of systematic reviews · 2024-09-12Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med (New York, N.Y.) · 2024-03-08Psychedelika-assistierte PsychotherapieDie Psychotherapie · 2024-02-28The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of ConsciousnessPsyArXiv · 2023-06-04The Altered Xperience Project (AXP): Quantitative and Qualitative Data from a Citizen Science Initiative on the Subjective Experience of Altered States of ConsciousnessPsyArXiv · 2023-06-04ID: 212703 Augmenting rTMS With Psilocybin-Assisted Psychotherapy (PAP) for PTSD: A Proof-of-Concept Study DesignNeuromodulation Technology at the Neural Interface · 2023-06-01[Attitudes of Mental Health Experts Towards Psilocybin].Fortschritte der Neurologie-Psychiatrie · 2023-03-01The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.Therapeutic advances in psychopharmacology · 2023-01-01Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.Psychopharmacology · 2022-06-01Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI).PloS one · 2022-01-01Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.American journal of psychotherapy · 2021-12-01Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)PsyArXiv · 2021-04-02Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI)PsyArXiv · 2021-04-02Dose-response relationships of psilocybin-induced subjective experiences in humans.Journal of psychopharmacology (Oxford, England) · 2021-04-01How does it feel to be on psilocybin? Dose-response relationships of subjective experiences in humansbioRxiv · 2020-06-11Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.Clinical pharmacokinetics · 2017-10-01[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].Fortschritte der Neurologie-Psychiatrie · 2017-07-01Alterations of consciousness and mystical-type experiences after acute LSD in humans.Psychopharmacology · 2017-05-01Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Journal of psychopharmacology (Oxford, England) · 2016-12-01The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.NeuroImage. Clinical · 2016-01-01Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?Journal of psychopharmacology (Oxford, England) · 2015-03-01Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.Cerebral cortex (New York, N.Y.: 1991) · 2014-12-01Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.The Journal of neuroscience: the official journal of the Society for Neuroscience · 2013-06-19Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual HallucinationsOpen MIND · 2013-01-01The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.Psychopharmacology · 2013-01-01Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.Biological psychiatry · 2012-12-01Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2012-03-01Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2003-01-01Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.Biological psychiatry · 2002-03-01177. NMDA and 5-HT2A receptor dysfunction in working memory deficits in schizophreniaBiological Psychiatry · 2000-03-31